These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38021444)

  • 21. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
    La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
    PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tanshinone IIA Reverses Gefitinib-Resistance In Human Non-Small-Cell Lung Cancer Via Regulation Of VEGFR/Akt Pathway.
    Wang R; Luo Z; Zhang H; Wang T
    Onco Targets Ther; 2019; 12():9355-9365. PubMed ID: 31807016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.
    Weng CH; Chen LY; Lin YC; Shih JY; Lin YC; Tseng RY; Chiu AC; Yeh YH; Liu C; Lin YT; Fang JM; Chen CC
    Oncogene; 2019 Jan; 38(4):455-468. PubMed ID: 30111817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extracellular Hsp90α clinically correlates with tumor malignancy and promotes migration and invasion in esophageal squamous cell carcinoma.
    Wang X; An D; Wang X; Liu X; Li B
    Onco Targets Ther; 2019; 12():1119-1128. PubMed ID: 30809093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
    Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
    Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
    Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
    Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells.
    Wei J; Li Y; Xu B; Yu J
    Am J Transl Res; 2020; 12(5):1640-1657. PubMed ID: 32509166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.
    Hu Y; Zang J; Qin X; Yan D; Cao H; Zhou L; Ni J; Yu S; Wu J; Feng JF
    Onco Targets Ther; 2017; 10():2341-2348. PubMed ID: 28496332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
    Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
    Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
    Okamoto W; Okamoto I; Tanaka K; Hatashita E; Yamada Y; Kuwata K; Yamaguchi H; Arao T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Mol Cancer Ther; 2010 Oct; 9(10):2785-92. PubMed ID: 20716641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
    Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
    BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1G6-D7 Inhibits Homologous Recombination Repair by Targeting Extracellular HSP90α to Promote Apoptosis in Non-Small Cell Lung Cancer.
    Du J; Zhang J; Liu D; Gao L; Liao H; Chu L; Lin J; Li W; Meng X; Zou F; Cai S; Zou M; Dong H
    Environ Toxicol; 2024 Jun; ():. PubMed ID: 38899512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.